Loading patent…
AssigneeOtsuka Pharmaceutical Co., Ltd.
InventorsKazuo Sekiguchi, Takashi Suzuki, Yutaka Ohbuchi, Mitsuhiro Okuno, Naoto Ohi, Kenji Ohnishi, Masaaki Motoyama, Kenji Yoshida, Takeshi Kodama, Kazuhisa Sugiyama, Seiji Akamatsu, Kunihiko Kiyono, Yasuo Yanagihara, Takashi Watanabe, Kazuhiko Hayashi, Hideo Tanaka, Takumi Sumida
Estimating the term…
An object of the present invention is to provide a STAT3/5 activation inhibitor. The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: wherein X1 represents a nitrogen atom or a group —CH═, R1 represents a group —Z—R6, in which Z represents a group —CO—, a group —CH(OH)— or the like, R6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents a group wherein R3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R4 represents an imidazolyl lower alkyl group or the like.
A method for inhibiting STAT3 activation in a patient having a symptom or disease selected from autoimmune disease, diabetes, infection, Alzheimer's disease, psoriasis, but not fibrosis, comprising administering, to said patient, an effective amount of a compound selected from the group consisting of:
A method for inhibiting STAT3 activation in a patient having a symptom or diseas e selected from autoimmune disease, diabetes, infection, Alzheimer's disease, psoriasis, but not fibrosis, comprising administering, to said patient, an effective amount of a compound selected from the group consisting of:
Dependencies are inferred from the claim text.